drugset
drugset / Trial / NCT04544215

A Clinical Study of Mesenchymal Progenitor Cell Exosomes Nebulizer for the Treatment of Pulmonary Infection

NCT04544215 ↗

Phase 1/2 Suspended 60 enrolled Ruijin Hospital Shanghai AbelZeta Ltd. · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

Evaluate the efficacy and safety of haMPC-Exos treatment with pulmonary infection caused by gram-negative bacilli resistant to carbapenems.

Timeline

Start
2020-07-01
Primary completion
2024-12-01
Completion
2025-03-01

Outcome

Outcome not reported

Stopped (Enrollment): “Due to the COVID-19 pandemic, patient enrollment was slower than expected. After enrolling 26 patients, the trial was suspended as our partner company stopped producing haMPC-Exos.”

Drugs

EvaluationDrugModalityDoseRoute
Subject haMPC-Exos Other / unclassified 8e+08 unknown Inhaled
Subject haMPC-Exos Other / unclassified 1.6e+09 unknown Inhaled

Indications

No indication recorded.